Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience

BACKGROUND: The antibody targeting platelet-derived growth factor receptor alpha (PDGFRA), olaratumab, was approved in 2016 for metastatic soft tissue sarcoma (STS) in combination with doxorubicin based on promising results of a phase Ib/II trial by the Food and Drug Administration (FDA). However, r...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:BMC Cancer
Hoofdauteurs: Striefler, Jana Käthe, Brandes, Franziska, Baur, Alexander, Pfitzner, Berit Maria, Kaul, David, Rau, Daniel, Dörr, Anne, Schmiester, Maren, Koulaxouzidis, Georgios, Bullinger, Lars, Märdian, Sven, Flörcken, Anne
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2020
Onderwerpen:
Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6988236/
https://ncbi.nlm.nih.gov/pubmed/31996176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-6551-y
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items